Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PepGen Inc. (PEPG)
NASDAQ:PEPG
Holding PEPG?
Track your performance easily
PEPG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $19.30
Previous CloseN/A
Volume7.67K
Average Volume (3M)233.43K
Market Cap
$78.88M
Enterprise Value$158.75M
Total Cash (Recent Filing)$9.78M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Mar 20, 2025EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.98
Shares Outstanding32,595,737
10 Day Avg. Volume132,123
30 Day Avg. Volume233,430
Standard Deviation0.26
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap2.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.85
Forecast
1Y Price Target
$15.33Price Target Upside566.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
PepGen Inc. News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPepGen's platform is validated by demonstrating the ability to deliver ASOs effectively to muscles and the nucleus, indicating robust potential for their technology.
Drug EfficacyPepGen has a solid opportunity to differentiate themselves from other candidates in DM1, since a blocking approach could translate to greater efficacy vs. degradation approaches.
Safety And PerformanceThe CONNECT1 data suggests that PGN-EDO51 has the potential to be best-in-class, highlighting promising safety and efficacy results.
Bears Say
Investment RatingThe investment rating for PepGen has been downgraded to Underperform from Neutral, reflecting concerns over the delayed progress and need for further validation of the EDO platform.
Market SpeculationThe decision to delay the reporting of 5mg/kg data for PGN-EDODM1 alongside 10mg/kg data raises market concerns that the 5mg/kg data may not have met expectations.
Regulatory IssuesThe FDA has placed a clinical hold on the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in Duchenne muscular dystrophy, which is a significant setback for PepGen's research progress.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $2.30 and its highest was $19.30 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $78.88M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Mar 20, 2025 which is in 58 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Nov 07, 2024. The company reported -$0.66 earnings per share for the quarter, beating the consensus estimate of -$0.868 by $0.208.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.81.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 32,595,737 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.66 in its last earnings report, beating expectations of -$0.868. Following the earnings report the stock price went down -21.697%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
---
PepGen Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.33 (566.52% Upside)
$15.33 (566.52% Upside)
Blogger Sentiment
Bullish
PEPG Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 174.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.37%
12-Months-Change
Fundamentals
Return on Equity
-66.26%
Trailing 12-Months
Asset Growth
3.63%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.
---
PEPG Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and a strong financial position due to recent funding, as well as regulatory advancements such as FDA fast track designation. However, there were challenges with increased expenses and a notable net loss for the year. Despite these financial lowlights, the clinical and regulatory achievements present a strong positive outlook.Read More>---
PEPG Stock 12 Month Forecast
Average Price Target
$15.33
▲(566.52% Upside)
Technical Analysis
Benitec Biopharma
―
RegenXBio
―
Fate Therapeutics
―
Intellia Therapeutics
―
Editas Medicine
―
Crispr Therapeutics AG
―
Best Analysts Covering PEPG
1 Year
1 Year Success Rate
4/13 ratings generated profit
1 Year Average Return
-18.45%
assigned a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -18.45% per trade.
---